- Home
- VTVT
VTVT
vTv Therapeutics Inc.
as 04-24-2025 10:45am EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HIGH POINT |
| Market Cap: | N/A | IPO Year: | 2015 |
| Target Price: | $35.50 | AVG Volume (30 days): | 10.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.12 - $29.19 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,017,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest vTv Therapeutics Inc. News
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
Zacks
a month ago
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Associated Press Finance
a month ago
VTv Therapeutics: Q4 Earnings Snapshot
GlobeNewswire
a month ago
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical Trials Arena
a month ago
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes
GuruFocus.com
a month ago
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial
GuruFocus.com
a month ago
FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress
MT Newswires
a month ago
Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell
GlobeNewswire
a month ago
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Compare VTVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.